ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.
Storytel AB is a prominent provider of streaming services for audiobooks and e-books, operating under the brands Storytel and Mofibo. Founded in 2005 and headquartered in Stockholm, Sweden, the company has established a significant presence in various countries, including Denmark, Norway, Finland, the Netherlands, and Poland, among others. Storytel's business is divided into two main segments: Streaming and Publishing. The Streaming segment offers subscription-based access to a vast library of digital content, while the Publishing segment includes several well-known imprints such as Norstedts and Massolit, as well as children's and young adult literature through B. Wahlström and Rabén & Sjögren. Additionally, Storytel has expanded its offerings to include digital subscriptions for newspapers and magazines, enhancing its portfolio in the publishing sector.
Mollie B.V. is a payments platform that specializes in online payment processing for merchants. Founded in 2004 and headquartered in Amsterdam, the Netherlands, Mollie serves over 50,000 clients by providing an easy-to-implement solution for integrating various payment methods into websites and applications. The platform supports a wide range of local payment options, including Mastercard, VISA, PayPal, iDEAL, and Bitcoin, among others. Mollie focuses on simplifying the payment process for merchants, eliminating complexities associated with multiple payment methods through a powerful and user-friendly API. The company emphasizes technology, innovation, and reliability in its services.
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).
Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. It specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus includes spinocerebellar ataxias, Huntington's disease, and Rett syndrome, which are characterized by progressive neurological decline and developmental challenges. Vico Therapeutics is committed to discovering and delivering innovative treatments that address the unmet medical needs of patients suffering from these severe conditions. Through its research and development efforts, the company seeks to provide effective therapeutic options for individuals affected by these disorders.
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, specializing in cell-based immunotherapy products for blood cancer treatment. The company is developing K-NK002, currently in Phase II clinical trials, as an adjunctive immunotherapeutic for blood cancer patients undergoing haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol. K-NK003 is another product in Phase I/II trials, targeting patients with acute myeloid leukemia relapse or refractory cases. Additionally, Kiadis Pharma is working on K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company has established collaborations for the development of a combination therapy involving monoclonal antibodies and natural killer cells to address COVID-19. Kiadis Pharma focuses on addressing the complications and limitations associated with hematopoietic stem cell transplants, offering novel treatment options for terminally ill cancer patients with significant unmet medical needs.
Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Veritas Petroleum Services (Asia) Pte Ltd. is a company specializing in testing, inspection, and advisory solutions tailored for the maritime industry. Founded in 1981 and based in Singapore, the company operates five laboratories in key global locations, including Rotterdam, Houston, and Fujairah. Veritas Petroleum Services assists ship operators, owners, and charterers in enhancing fuel management and operational efficiency while ensuring compliance with marine fuel regulations. Its services include fuel quality testing, fuel system checks, troubleshooting analysis, drinking water analysis, and bunker quantity surveys. Additionally, the company provides sampling equipment to help clients collect representative samples of delivered bunker fuels. Formerly known as DNV Petroleum Services Pte Ltd., the company rebranded in July 2014 and has expanded its customer service presence to multiple cities worldwide, including New Jersey, Tokyo, and London.
Dunlop Protective Footwear is the leading global manufacturer of protective wellington boots. In more than 50 countries worldwide, the Company provides comfortable and protective footwear to the workers in Agriculture & Fishery, Food processing, Industry and the Oil, Gas & Mining industry. Dunlop has more than 500 employees, three production sites in the Netherlands, Portugal and the US, and sales people around the world. Dunlop Protective Footwear is headquartered in Raalte, the Netherlands.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.
Caiway is a telecom infrastructure company based in Naaldwijk, Netherlands, specializing in broadband, television, and telephony services. The company operates broadband connections to over 350,000 households and businesses, focusing on both urban and remote areas. In recent years, Caiway has expanded its fiber networks to enhance connectivity in municipalities and homes, establishing itself as a strong regional internet service provider. Key regions within Caiway's service area include Westland, Schiedam, and Almelo. By leveraging advanced cable and fiber infrastructure, Caiway aims to deliver reliable networking and high-quality services to its customers.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
DentConnect is a fast-growing platform of dental clinics, with activities in the Netherlands, Belgium, Denmark, Germany and Italy. DentConnect is headquartered in the Netherlands and serves over one million patients through its pan-European network of over 220 clinics. DentConnect acts as a multi-functional service organization for these clinics, allowing the dentists to fully focus on providing patients with the best possible care. DentConnect Shared Service Center supports and facilitates dentists with HR, Finance and administration, quality and care management, procurement, marketing and communication and general management.
Delta Comfort offers multimedia and energy solutions to residential and business clients in the province of Zeeland. Delta Comfort owns and operates a hybrid fiber-coaxial (HFC) network of 3,400km of fiber and 3,000km of coaxial cables, which passes 192,000 households in the region. Delta Comfort employs approximately 370 people and generated sales of EUR 214 million in 2015. It is headquartered in Middelburg, the capital of Zeeland, Netherlands.
Private Equity Round in 2016
TransIP Group B.V. is a Netherlands-based company that specializes in virtual private servers, domain name registration, and web hosting services. Founded in 2003, it primarily serves tech-savvy customers and information technology professionals in the Benelux region. TransIP offers a range of products, including BladeVPS PureSSD Pro, a self-managed tool equipped with web control panels and operating systems, as well as STACK, an online storage solution for file management. The company also provides SSL certificates to secure website connections, along with additional services such as forwarding, large storage options, and private networks. As of May 2019, TransIP operates as a subsidiary of Combell nv.
Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.
Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
Bureau van Dijk Electronic Publishing BV specializes in providing comprehensive business information solutions, focusing on both public and private companies. Founded in 1991 and headquartered in Amsterdam, the company aggregates, cleans, and analyzes data on corporate structures and financials, offering insights for various sectors including finance, corporate, and public domains. Its extensive portfolio includes tools for transfer pricing, corporate valuation, credit analysis, compliance, and procurement, as well as databases containing economic indicators and forecasts. Bureau van Dijk also supports clients with tools for mergers and acquisitions, client onboarding, and market analysis, catering to a diverse clientele that includes banks, insurance companies, and academic institutions. As a subsidiary of Moody's Analytics since 2017, Bureau van Dijk continues to enhance its offerings through collaborations with leading information providers, enabling clients to make informed decisions and operate efficiently in a complex business environment.
Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, specializing in cell-based immunotherapy products for blood cancer treatment. The company is developing K-NK002, currently in Phase II clinical trials, as an adjunctive immunotherapeutic for blood cancer patients undergoing haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol. K-NK003 is another product in Phase I/II trials, targeting patients with acute myeloid leukemia relapse or refractory cases. Additionally, Kiadis Pharma is working on K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company has established collaborations for the development of a combination therapy involving monoclonal antibodies and natural killer cells to address COVID-19. Kiadis Pharma focuses on addressing the complications and limitations associated with hematopoietic stem cell transplants, offering novel treatment options for terminally ill cancer patients with significant unmet medical needs.
Prosensa is a biopharmaceutical company that specializes in the discovery, development, and commercialization of RNA-based therapeutics. It is particularly focused on addressing genetic disorders, with a primary emphasis on neuromuscular conditions. The company recognizes significant market opportunities in the healthcare sector for innovative products targeting genetic disorders, anti-infectives, and oncology. To maximize commercial potential, Prosensa plans to leverage its strong intellectual property position while primarily outsourcing its operations to specialized organizations. Through this strategy, the company aims to develop novel therapeutics that can address unmet medical needs in various therapeutic areas.
Atos Medical was founded in 1986 and today has a vast international network with subsidiaries in the USA, UK, Germany, Spain, Netherlands, Belgium, Sweden and Switzerland and also exclusive distributors serving about 60 countries. The head office is situated in Sweden, where a state-of-the-art clean room and laboratory make it possible to perform all tests required for successful R&D.
Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, the company aims to enhance patient comfort and therapeutic outcomes with its innovative, high-resolution, and MRI-compatible DBS system. Sapiens specializes in developing a comprehensive DBS solution that includes navigation and steering software, as well as implants specifically designed for patients with Parkinson's disease. With offices in Eindhoven, the Netherlands, and Munich, Germany, Sapiens leverages patented technologies to deliver effective and precise treatment options for individuals suffering from this neurological condition.
Koole is an independent international storage and transport company specialising in vegetable oils and fats, oleochemicals, waxes, biodiesel, base oils, non-hazardous chemicals and minerals.
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
Kreatech Holding BV is a molecular diagnostics company focused on the development and commercialization of innovative detection products. These are used for diagnostic and research applications in the life sciences and healthcare industry.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.
Kreatech Holding BV is a molecular diagnostics company focused on the development and commercialization of innovative detection products. These are used for diagnostic and research applications in the life sciences and healthcare industry.
BMEYE B.V. is a Netherlands-based company focused on the research and development of non-invasive cardiovascular monitoring technologies. Established in 2005 and located in Amsterdam, BMEYE specializes in devices that measure blood pressure and cardiac output. Its product lineup includes the Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version of the same technology; and the Finometer, a stationary monitor that provides non-invasive brachial pressure measurements. Additionally, BMEYE offers BeatScope, a software tool for analyzing arterial pressure waveforms, and Modelflow, a method for computing aortic flow waveforms. The company also has various devices like Cardiopres and Oxyflow for specific applications in research and clinical settings. BMEYE's products are distributed through a network of distributors and have received approval for sale in the U.S. and Europe, particularly targeting markets such as cardiology and anesthesia.
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, specializing in cell-based immunotherapy products for blood cancer treatment. The company is developing K-NK002, currently in Phase II clinical trials, as an adjunctive immunotherapeutic for blood cancer patients undergoing haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol. K-NK003 is another product in Phase I/II trials, targeting patients with acute myeloid leukemia relapse or refractory cases. Additionally, Kiadis Pharma is working on K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company has established collaborations for the development of a combination therapy involving monoclonal antibodies and natural killer cells to address COVID-19. Kiadis Pharma focuses on addressing the complications and limitations associated with hematopoietic stem cell transplants, offering novel treatment options for terminally ill cancer patients with significant unmet medical needs.
Prosensa is a biopharmaceutical company that specializes in the discovery, development, and commercialization of RNA-based therapeutics. It is particularly focused on addressing genetic disorders, with a primary emphasis on neuromuscular conditions. The company recognizes significant market opportunities in the healthcare sector for innovative products targeting genetic disorders, anti-infectives, and oncology. To maximize commercial potential, Prosensa plans to leverage its strong intellectual property position while primarily outsourcing its operations to specialized organizations. Through this strategy, the company aims to develop novel therapeutics that can address unmet medical needs in various therapeutic areas.
BMEYE B.V. is a Netherlands-based company focused on the research and development of non-invasive cardiovascular monitoring technologies. Established in 2005 and located in Amsterdam, BMEYE specializes in devices that measure blood pressure and cardiac output. Its product lineup includes the Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version of the same technology; and the Finometer, a stationary monitor that provides non-invasive brachial pressure measurements. Additionally, BMEYE offers BeatScope, a software tool for analyzing arterial pressure waveforms, and Modelflow, a method for computing aortic flow waveforms. The company also has various devices like Cardiopres and Oxyflow for specific applications in research and clinical settings. BMEYE's products are distributed through a network of distributors and have received approval for sale in the U.S. and Europe, particularly targeting markets such as cardiology and anesthesia.
DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).
OctoPlus is a specialty pharmaceutical company globally renowned for its expertise in pharmaceutical development of injectables and is based on the bioscience park, one of the leading bioscience industry parks in Europe. The company employs around 120 people, and is highly culturally diverse, with over 20 different nationalities represented in its workforce.
PamGene International B.V. is a biomarker company based in s-Hertogenbosch, the Netherlands, specializing in a proprietary array-based platform that measures the activities of kinases and nuclear receptors. This technology supports a variety of applications, including lead identification and optimization, pre-clinical translational research, and biomarker development, particularly in oncology and medicine. Key products include the PamStation, an automated instrument for processing microarrays, and the PamChip, which is utilized on the PamStation to analyze various kinases and receptors. The BioNavigator software facilitates data interpretation and visualization. Additionally, PamGene provides training, consulting services, and a suite of online resources through Pamcloud, which encompasses an encyclopedia, a comprehensive database, and training materials related to kinases and nuclear receptors. Founded in 1999, PamGene operates as a subsidiary of Vitromics Healthcare Holding B.V.
PamGene International B.V. is a biomarker company based in s-Hertogenbosch, the Netherlands, specializing in a proprietary array-based platform that measures the activities of kinases and nuclear receptors. This technology supports a variety of applications, including lead identification and optimization, pre-clinical translational research, and biomarker development, particularly in oncology and medicine. Key products include the PamStation, an automated instrument for processing microarrays, and the PamChip, which is utilized on the PamStation to analyze various kinases and receptors. The BioNavigator software facilitates data interpretation and visualization. Additionally, PamGene provides training, consulting services, and a suite of online resources through Pamcloud, which encompasses an encyclopedia, a comprehensive database, and training materials related to kinases and nuclear receptors. Founded in 1999, PamGene operates as a subsidiary of Vitromics Healthcare Holding B.V.
Haanpaa is a logistics company specializing in the distribution of chemical products across Europe. Founded in 1949 by Jussi Haanpaa and headquartered in Vantaa, Finland, the company offers a range of services including storage, maintenance, transportation, and delivery in various European cities. Haanpaa also engages in sampling, monitoring, and packaging of chemical products, along with tank inspection and customer support services. The company produces specialty chemicals, pulps and papers, fuels, lubricants, animal feeds, and agricultural commodities. With branches in Finland, Sweden, Norway, Estonia, Russia, and the Netherlands, Haanpaa has established a strong presence in the logistics sector for liquid chemical products. Since July 2016, it has operated as a subsidiary of Groupe Samat SA.